Research has revealed that some NHL patients, especially B-cell lymphoma patients, overexpress BCL-2, which promotes tumor cell resistance to chemotherapy drugs and is associated with poor prognosis [95]. The gene discussed is BCL2; the disease is B-cell non-Hodgkin lymphoma.